Examkin

Soru

Zorluk: Çok zorMenstrual Cycle Abnormalities and Contraception

An academic medical center runs a specialized complex contraception clinic. Four patients present seeking highly effective, reversible contraception. Match each patient's presentation and medical history with the single most appropriate contraceptive method based on the World Health Organization Medical Eligibility Criteria (WHO MEC) and potential secondary clinical benefits.

  • A 31-year-old woman with epilepsy taking carbamazepine presents with severe fatigue. Urine beta-hCG is negative. Laboratory studies show a hemoglobin of 9.2 g/dL9.2 \text{ g/dL}. She reports heavy menstrual bleeding saturating 66 to 88 pads daily. Vital signs and pelvic examination are normal.Levonorgestrel-releasing intrauterine device
  • A 38-year-old woman with a history of unprovoked deep vein thrombosis 33 years ago and Roux-en-Y gastric bypass 11 year ago (current BMI 26 kg/m226 \text{ kg/m}^2). Urine beta-hCG is negative. Ultrasound confirms a 6-cm6\text{-cm} submucosal leiomyoma significantly distorting the endometrial cavity.Subdermal etonogestrel implant
  • A 34-year-old woman presents 66 months after surgical resection of an estrogen receptor-positive ductal carcinoma in situ. She is currently taking tamoxifen and is amenorrheic. Serum beta-hCG is negative. Physical examination shows no pelvic masses or abnormalities.Copper-releasing intrauterine device
  • A 28-year-old woman with homozygous sickle cell disease experiences frequent vaso-occlusive pain crises requiring hospitalization. Urine beta-hCG is negative. Vital signs are stable. She strongly desires a method that might provide secondary disease-modifying benefits.Depot medroxyprogesterone acetate injection

Cevap

The epilepsy patient matches with the Levonorgestrel-releasing intrauterine device. The patient with prior DVT, gastric bypass, and a distorted cavity matches with the Subdermal etonogestrel implant. The breast cancer patient matches with the Copper-releasing intrauterine device. The sickle cell disease patient matches with the Depot medroxyprogesterone acetate injection.
Each clinical profile maps uniquely to one contraceptive method based on overlapping WHO MEC guidelines. The epilepsy patient requires a method unaffected by CYP inducers that also controls bleeding (LNG-IUD). The complex bariatric/fibroid patient requires a non-oral, non-estrogen, non-intrauterine method (Implant). The breast cancer patient must avoid all hormones completely (Copper IUD). The sickle cell patient derives unique hematologic benefits from DMPA.

Adım Adım Çözüm

1
Evaluate eligibility for the patient with epilepsy, carbamazepine use, and heavy menstrual bleeding.
Identify the Levonorgestrel-releasing intrauterine device as the optimal choice.
CYP450 inducers like carbamazepine lower the efficacy of systemic hormones. The LNG-IUD is unaffected (MEC 1) and uniquely treats her symptomatic heavy bleeding.
2
Evaluate eligibility for the patient with a prior DVT, Roux-en-Y bypass, and a submucosal fibroid.
Identify the Subdermal etonogestrel implant as the optimal choice.
Estrogen is strictly contraindicated due to DVT (MEC 4). Malabsorption from gastric bypass reduces oral pill efficacy (MEC 3). The distorted cavity prevents IUD placement (MEC 4). The implant safely addresses all constraints.
3
Evaluate eligibility for the patient with estrogen receptor-positive breast cancer taking tamoxifen.
Identify the Copper-releasing intrauterine device as the optimal choice.
Active or recent breast cancer strictly contraindicates all hormonal methods (MEC 4). Only hormone-free methods, such as the highly effective copper IUD, are safe.
4
Evaluate eligibility for the patient with sickle cell disease and frequent crises.
Identify the Depot medroxyprogesterone acetate injection as the optimal choice.
DMPA provides excellent contraception and uniquely offers secondary disease-modifying benefits by significantly reducing the frequency of vaso-occlusive sickle cell crises.

Anahtar Kavram

Integration of the WHO Medical Eligibility Criteria (MEC) across complex patient profiles, emphasizing drug interactions, anatomical constraints, oncologic contraindications, and secondary non-contraceptive benefits.
Bu soruyu puanla

Konular

Menstrual Cycle Abnormalities and Contraception

Bu konudan daha fazla soru